



# Claim CE credit by TEXTING the code after the activity.

**What you need to do:**

**Ensure your mobile number is  
linked to your profile.**

The screenshot shows the Advocate Health website with a navigation bar at the top. The navigation bar includes links for HOME, COURSES, GRAND ROUNDS/CASE CONFERENCES, RESOURCES, CE PRE PLANNING FORM, and CONTACT US. Below the navigation bar is a search bar with the placeholder 'Find a course...' and a magnifying glass icon. To the right of the search bar are social media icons for Facebook, Twitter, LinkedIn, and a mobile device. The main content area has a dark blue header bar with the text 'My Account'. Below this are several buttons: 'My Account' (with a person icon), 'My Pending Activities' (with a document and pencil icon), 'My Transcript' (with a document icon), 'Edit My Profile' (with a person and gear icon), and 'Add/Edit Mobile Number' (with a smartphone icon). The 'Add/Edit Mobile Number' button is highlighted with a red rectangular box.

# Welcome to the January 2026 Nursing Grand Rounds

## Empowering Nurses in Patient Blood Management: Every Drop Counts!

### This is a Microsoft Teams Meeting with Contact Hours

- Focus is on the presenters with all participants muted
- Participants are encouraged to post questions/comments in the “Q&A” They will be addressed during the Q & A session at the end
- Details about evaluation and contact hours will be provided at the end
  - REMINDER – now a text code process – make sure your cell number is updated in the CE Learning platform in order to receive CEs
- Session is recorded and will be available as a digital self-learning module with continuing education credit on the CE Learning platform
- Please visit the Nursing Grand Rounds webpage for direct links.



# ENTERPRISE NURSING GRAND ROUNDS

## Did you Bring a Friend?

**TODAY ONLY!!!** For every friend you bring, all attending today's live session, your name will be entered in a raffle to win a \$25 Advocate Teammate Store Gift Card.

Winner will be announced on Monday, 1/19 after verifying attendance.

Entry form link is in the Q & A or scan the QR code



# Disclosure:

None of the planners or presenters for this educational activity have relevant financial relationships to disclose with ineligible companies

## IPCE Designation and Accreditation



### Accreditation Statement

In support of improving patient care, Advocate Aurora Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Credit Statement(s)

#### American Nurses Credentialing Center (ANCC)


Advocate Aurora Health designates this live activity for a maximum of 1.0 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

# Learner Objectives

At the end of this session, learners should be able to:

1. Identify strategies for early detection and management of anemia to optimize patient outcomes.
2. Apply Patient Blood Management (PBM) practices in nursing care to minimize unnecessary transfusions, including single-unit transfusions and reassessment protocols.
3. Demonstrate the nurse's role in PBM through assessment, communication, and advocacy for safe, patient-focused transfusion practices.
4. Evaluate clinical and safety risks of allogeneic blood transfusions and integrate bloodless medicine principles for patients who decline blood components.





## AUDIENCE POLL

**Which division and care environment are you attending from?**



Advocate Health Care



Atrium Health



Aurora Health Care



Wake Forest University  
School of Medicine

Now part of  ADVOCATEHEALTH

# *Empowering Nurses in Patient Blood Management: Every Drop Counts*

**Laura Yau, MSN, RN – Charlotte Area**


**Chandler Purser, BSN, RN, BMTCN – Georgia Area**

**Bobbi Jo Tutterow, MSN, RN – Wake Area**

**Beth Halperin, BSN, RN – Midwest**

**Nursing Grand Rounds 01.15.2026**

# Presentation Overview






**ADVOCATE**HEALTH

# **Blood Transfusion is a Transplant**

**Laura Yau, MSN, RN, ACCNS-AG**  
**Charlotte Area**




## AUDIENCE POLL

**Word cloud: Name a risk of blood transfusion.**

# Blood Transfusion = Liquid Transplant



**Each unit of blood is a new “transplant” of foreign tissue and cells causing its own independent impact on the recipient**



**Figure 1: Transfusion-Associated Fatalities by Complication, FY2018 – FY2022**

Note: FY2018-FY2022 only includes cases with an imputability of *definite, probable, or possible*

\*FY2018-FY2022 numbers combine both *TRALI* and *Possible TRALI* cases



# Transfusion Associated Circulatory Overload (TACO)




Causes the highest percentage of reported transfusion related fatalities

- 13 fatalities in 2022 = 44% of reported fatalities

Symptoms within 12 hours of transfusion:

- Respiratory distress and/or Pulmonary edema
- Elevated BNP
- Cardiovascular system changes
- Evidence of fluid overload

# Transfusion Related Acute Lung Injury (TRALI)



## Fatal reaction


- 3 fatalities in 2022 = 10% of reported fatalities

## Symptoms within 6 hours of transfusion<sup>2</sup>:

- Acute lung injury
- Hypoxemia
- Radiographic evidence of bilateral infiltrates
- No evidence of left atrial hypertension (i.e. circulatory overload)

	TRALI	TACO
Definition	Fluid leakage into alveolar space due to diffuse alveolar capillary damage caused by neutrophils	Volume overload due to rapid transfusion of large volumes of blood products
Presentation	Noncardiogenic pulmonary edema	Cardiogenic pulmonary edema
Risk Factors	<u>Patient-related:</u> Critically ill patients receiving plasma-containing blood products <u>Blood product-related:</u> Plasma containing blood products donated from multiparous females	<u>Patient-related:</u> Older patients with comorbidities, mainly CHF and CKD, or small patients <u>Blood product-related:</u> Massive infusion of blood products, high rates
Symptoms	Increased RR, acute dyspnea, hypoxemia, hypotension. Possible fever	Increased RR, acute dyspnea with features of volume overload: High CVP, Peripheral edema, JVD, hypertension. Occasional fever
Laboratory <i>Chest radiograph</i>	Transient Leukopenia, BNP <200 pg/ml, normal EF <i>Diffuse, bilateral infiltrates</i>	Unchanged WBC, BNP >1200 pg/ml, low EF <i>Diffuse, bilateral infiltrates</i>
Treatment	Supportive (O <sub>2</sub> , noninvasive/invasive ventilation), fluids/pressors, not responsive to diuretics	Supportive (O <sub>2</sub> , noninvasive/invasive ventilation), responsive to diuretics

# Hemolytic Transfusion Reaction




6 fatalities in 2022<sup>1</sup>

Acute (within 24 hours) or Delayed (24 hours to 28 days)



Symptoms of acute:

Signs/Symptoms (Any of below)	And 2 or more lab findings:
Back/flank pain	Decreased fibrinogen
Chills/rigors	Decreased haptoglobin
Disseminated intravascular coagulation (DIC)	Elevated bilirubin
Epistaxis (nosebleed)	Elevated LDH
Fever	Hemoglobinemia
Hematuria	Hemoglobinuria
Hypotension	Plasma discoloration
Oliguria/anuria	Spherocytes
Pain and/or oozing at IV site	Positive direct antiglobulin test (DAT)
Renal failure	Positive eluate

# Hemolytic Transfusion Reaction




## ABO Antigens & Antibodies

	Type A	Type B	Type AB	Type O
Red Blood Cell				
Antigens on RBC	A antigen 	B antigen 	A antigen  B antigen 	No antigens (Universal RBC donor)
Antibodies in Plasma	Anti-B 	Anti-A 	No Antibody (Universal plasma donor)	Anti-A  Anti-B 

Used with permission by S. Weiss

## Blood Groups on the RBC



Nydegger, U.E. and Flegel, W.A

There are over 300 different red cell antigens that a patient could make an antibody against.

# Allergic Reaction

4 fatalities in 2022 due to anaphylactic reaction

Symptoms of allergic reaction (2 or more within 4 hours of transfusion)

- Conjunctival edema
- Edema of lips, tongue and uvula
- Erythema and edema of the periorbital area
- Generalized flushing
- Hypotension
- Localized angioedema
- Macropapular rash
- Pruritus (itching)
- Respiratory distress; bronchospasm
- Urticaria (hives)

# Bacterial Contamination

1 fatality in 2022

Laboratory evidence of a pathogen in the recipient

THE JOURNAL OF AABB

transfusion.org

# TRANSFUSION

CASE REPORT

## Fatal sepsis associated with a storage container leak permitting platelet contamination with environmental bacteria after pathogen reduction

Emmanuel A. Fadeyi , Stephen J. Wagner, Corinne Goldberg, Thea Lu, Pampee Young, Peter W. Bringmann, Nathaniel M Meier, Andrew M. Namen, Richard J. Benjamin, Elizabeth Palavecino

First published: 08 December 2020 | <https://doi.org/10.1111/trf.16210> | Citations: 24

# United States: RBC transfusion utilization is high and often unwarranted

---

**12 million** RBC units are transfused annually in the U.S.

**1 in 10** hospitalized patients who undergoes an invasive procedure is transfused

**40% to 60%** of transfusions are unwarranted, according to published research studies

**Variability in care** suggests the decision to transfuse is led by behavior rather than evidence

From the Society for the Advancement of Blood Management, *Transfusion Overuse*, 2019.

# Why Make Patient Blood Management a Priority?


## Blood Transfusion is Not Benign & Transfusion Overuse Is Pervasive

Transfusion is associated with increased risk of hospital-acquired infection and cancer recurrence (immunomodulation)


Transfusion is associated with increased cardiac, renal & pulmonary complications (pro-inflammatory, pro-thrombotic)

Transfusion is associated with increased risk re-bleeding and mortality in GI bleed, cardiac surgery, and critical care

Current evidence has defined a **narrow therapeutic window** for transfusion: **Less IS More**



# Patient Blood Management



**Definition:** cPBM is a patient-centered, systematic, evidence-based approach to improving patient outcomes by managing and preserving a patient's **own** blood, while promoting patient safety and empowerment.

Vision - Make cPBM (Patient Blood Management, Anemia Management and Bloodless Medicine & Surgery) a standard of care for all patients. **It should not be an option but be hardwired as Advocate Health's standard.**

## Comprehensive Patient Blood Management

Improving Quality and Patient Safety

Diagnose and Manage  
Anemia

Avoid Unnecessary  
Transfusion

Bloodless  
Medicine & Surgery

The 3 Equal Pillars of Blood Management

# Transfusion Guidelines



## Atrium Evidence-Based Transfusion Recommendations

### RED BLOOD CELLS

<ul style="list-style-type: none"> <li>Active bleeding independent of hemoglobin</li> </ul>	
Hgb <7 g/dL	<ul style="list-style-type: none"> <li>Signs or symptoms of anemia unresponsive to management without transfusion</li> <li>Stable ischemic heart disease and signs or symptoms of anemia unresponsive to management without transfusion</li> <li>Acute upper gastrointestinal hemorrhage</li> <li>Sepsis</li> <li>Marrow suppression due to chemotherapy and/or radiotherapy</li> </ul>
Hgb <7.5 g/dL	<ul style="list-style-type: none"> <li>Undergoing cardiac surgery</li> <li>Bone marrow suppression or bone marrow failure AND long-term transfusion dependency whose anemia cannot be managed with erythropoiesis-stimulating agents and/or intravenous iron</li> </ul>
Hgb <8.0 g/dL	<ul style="list-style-type: none"> <li>Acute coronary syndrome or evidence to support the need for increased O<sub>2</sub> delivery indicated by any of the following           <ul style="list-style-type: none"> <li>Tachycardia and/or hypotension unresponsive to pharmacologic therapy</li> <li>New EKG changes</li> <li>Recurrent chest pain</li> <li>Acute respiratory failure, inadequate cardiac output, or inadequate oxygenation despite optimal ventilatory support</li> </ul> </li> </ul>
<ul style="list-style-type: none"> <li>Sickle cell disease – review ASH 2020 guidelines or consult hematology</li> </ul>	

### PLASMA

In a non-bleeding patient IV Vitamin K is the first-line therapy. In a bleeding patient, PCC is the first-line therapy. If PCC or Vitamin K is unavailable or contraindicated, follow the guidelines below.

INR >3.0	<ul style="list-style-type: none"> <li>Paracentesis for liver disease – Viscoelastic testing recommended</li> </ul>
INR >2.0	<ul style="list-style-type: none"> <li>LOW bleeding risk procedures for example           <ul style="list-style-type: none"> <li>Emergent surgical intervention</li> <li>For a full list, see complete Adult Transfusion Guidelines</li> </ul> </li> </ul>
INR >1.7	<ul style="list-style-type: none"> <li>Epidural placement or removal</li> <li>Surgery involving the neuroaxis</li> <li>Large-bore tunneled CVC insertion with clinical and laboratory evidence of coagulopathy</li> <li>Intracranial hemorrhage</li> </ul>
INR >1.5	<ul style="list-style-type: none"> <li>HIGH bleeding risk procedures for example           <ul style="list-style-type: none"> <li>For a full list, see complete Adult Transfusion Guidelines</li> </ul> </li> </ul>
<ul style="list-style-type: none"> <li>Massive Transfusion Protocol</li> <li>Plasma exchange in Thrombotic Thrombocytopenic Purpura (TTP)</li> <li>Hemorrhage and PTT &gt; 50 seconds due to factor deficiency for which no factor concentrate is available (rule out heparin and anti-phospholipid antibody before considering plasma transfusion)</li> </ul>	

Full guidelines and references available in Policy Tech

THRESHOLD	PLATELETS	
	CLINICAL SCENARIO	PROPHYLACTIC
PLT ≤ 10 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Hypoproliferative thrombocytopenia (marrow failure or suppression)</li> </ul>
PLT ≤ 20 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Hypoproliferative thrombocytopenia (marrow failure or suppression) and presence of minor bleeding or additional risk factors for bleeding</li> </ul>
PERI-PROCEDURAL		
PLT ≤ 20 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>LOW bleeding risk procedures for example           <ul style="list-style-type: none"> <li>Endoscopy or bronchoscopy without biopsy</li> <li>Central line placement</li> <li>Paracentesis or thoracentesis</li> <li>For a full list, see complete Adult Transfusion Guidelines</li> </ul> </li> </ul>
PLT ≤ 30 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Vaginal delivery</li> </ul>
PLT ≤ 50 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>HIGH bleeding risk procedures for example           <ul style="list-style-type: none"> <li>Arterial interventions: &gt; 7-F sheath, aortic, pelvic, mesenteric, CNS</li> <li>Percutaneous or endoscopic solid organ biopsies</li> <li>General surgery and gynecological surgery (including C-sections)</li> <li>For a full list, see complete Adult Transfusion Guidelines</li> </ul> </li> </ul>
PLT ≤ 80 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Epidural catheter insertion or removal</li> </ul>
PLT ≤ 100 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Neurosurgery or retinal surgery</li> </ul>
THERAPEUTIC		
PLT ≤ 50 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Post-surgical or post-procedural bleeding</li> <li>Significant Non-procedural related bleeding</li> <li>Massive transfusion protocol</li> </ul>
PLT ≤ 80 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Cardiac surgery with unexpected bleeding</li> </ul>
PLT ≤ 100 x10 <sup>3</sup> /uL		<ul style="list-style-type: none"> <li>Neuraxial bleeding</li> </ul>
CRYO		
FIB <200 mg/dL		<ul style="list-style-type: none"> <li>Ongoing hemorrhage in obstetrical, trauma, and cardiothoracic surgery</li> </ul>
FIB <125 mg/dL		<ul style="list-style-type: none"> <li>In acute promyelocytic leukemia</li> </ul>
		<ul style="list-style-type: none"> <li>Massive transfusion protocol</li> <li>Congenital fibrinogen deficiency and bleeding</li> <li>Factor VIII and Factor XIII deficiency with bleeding when specific factor concentrates are not available. Hematology consult recommended</li> <li>vWWD with bleeding or prior to urgent invasive procedure when specific concentrates are not available or DDAVP is contraindicated or unavailable</li> </ul>

These are recommendations for transfusion decision making and are not a substitute for clinical judgement. Not all patients who meet the criteria in these recommendations will require transfusion, other appropriate therapies must be considered. In certain clinical circumstances, transfusion of a blood component may be appropriate outside of these recommendations. The decision to transfuse is a clinical decision based on real-time assessment of the patient. There may be additional factors to consider when making transfusion decisions in the outpatient settings. In all circumstances, the indication for transfusion and supporting data should be documented in the medical record.

ALTH

# WHEN THERE IS A NEED FOR TRANSFUSION **LESS is MORE**

## WHAT YOU NEED TO KNOW

### 1 NOT 2

Transfuse the minimal amount of RBC units followed by a clinical assessment for the need of additional transfusions



### 7 NOT 8


Transfuse RBC at Hgb less than 7.0 g/dl in stable patients

# Sharing Transfusion Practice Data

## Red Blood Cell Metric Scorecard

Date Range: 9/1/2025 - 11/30/2025

Favorable  Caution  Unfavorable  No Target



Facilities: All

Specialties: All

Patient Types: All

Provider Groups: All


Providers: All

# Sharing Transfusion Practice Data

## Red Blood Cell Hemoglobin Facility Ranking (Rank 1-20)



% Single Unit Tx	81%
Target > 84%	
% Hgb < 7	60%
Target > 77%	
% Hgb ≥ 8	11%
Target < 5%	
Avg Pre Tx Hgb	6.9
Target < 7 g/dL	
Transfused Units	16,822
No Target	



# References

1. [Fatalities Reported to FDA Following Blood Collection and Transfusion, Annual Summary for Fiscal Year 2022](#)
2. [National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol](#), March 2025
3. Fadeyi EA, Wagner SJ, Goldberg C et al. Fatal sepsis associated with a storage container leak permitting platelet contamination with environmental bacteria after pathogen reduction. *Transfusion*. 2021;61(2):641-648. doi: 10.1111/trf.16210
4. Steele WR, Dodd RY, Notari EP, et al for the Transfusion-Transmissible Infections Monitoring System (TTIMS). HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men. *Transfusion* 2021;61(3):839-50.
5. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. *Lancet* 2007; 370:415-26.
6. Huish S, Green L, Kempster C, et al. A comparison of platelet function in cold-stored whole blood and platelet concentrates. *Transfusion* 2021;61:3224-35.
7. Cohn, Delaney, Johnson, Katz, Schwartz, eds. *Technical Manual*. 21st ed. AABB; 2023.
8. Hovav T, Yedgar S, Manny N, Barshtein G. Alteration of red cell aggregability and shape during blood storage. *Transfusion*. 1999;39(3):277-281. <https://doi-org.wake.idm.oclc.org/10.1046/j.1537-2995.1999.39399219284.x>
9. Yazer MH, Triulzi DJ. Detection of anti-D in D- recipitnes transfused with D+ red blood cells. *Transfusion* 2007;47:2197-201.
10. Yazer MH, Delaney M, Doughty H, et al. It is time to reconsider the risks of transfusing RhD negative females of childbearing potential with RhD positive red blood cells in bleeding emergencies. *Transfusion* 2019; 59:3794-9.
11. Sihler KC, Napolitano LM. Complications of massive transfusion. *Chest* 2010;137(1):209-20.
12. Tobian AA, King KE, Ness PM. Transfusion premedications: A growing practice not based on evidence. *Transfusion* 2007; 47:1089-96.
13. Peters AL, Van Stein D, Vlaar AP. Antibody-mediated transfusion-related acute lung injury; from discovery to prevention. *BR J Haematol* 2015; 170(5):597-614.




**ADVOCATE** HEALTH

# **Anemia is NOT “Normal”: Empowering Nurses to Detect, Prevent, and Advocate**

**Chandler Purser, BSN, RN, BMTCN**


**Georgia Area**



## AUDIENCE POLL

**At what hemoglobin level is anemia diagnosed?**

- 7g/dL
- 11g/dL
- 13g/dL
- Unsure



## AUDIENCE POLL

**At what hemoglobin level is anemia diagnosed?**

Recent literature defines anemia as a hemoglobin **<13 g/dL** for **BOTH** men and women.

Lower values are often deemed “normal,” but this is misleading and can be dangerous for patients, leading to suboptimal outcomes.



**ADVOCATE**HEALTH

# SURVEY STUDY ON NURSES' UNDERSTANDING OF ANEMIA MANAGEMENT IN HOSPITALIZED PATIENTS

PAM BAKER, RN, LEIGH GRANT, BSN, RN, CHANDLER PURSER, BSN, RN, BMTCN,  
BOBBI JO TUTTEROW, MSN, RN, LAURA YAU, MSN, RN, SHERRI OZAWA, MSN, RN

Nurses surveyed across the NC/GA Division overwhelmingly believe anemia negatively impacts patient outcomes, yet many feel that their teams only prioritize anemia in emergencies.



outreach aimed to collect more comprehensive feedback, strengthen the reliability of results, and gain deeper insights into nurses' knowledge of anemia management in hospitalized patients.

hospitalized patients, contributing to adverse outcomes and increased healthcare costs. Nurses play a vital role in the multidisciplinary early. Limited research exists on nurses' knowledge and confidence in managing anemia. Understanding the nurse's knowledge of anemia management is essential for improving patient outcomes and reducing healthcare costs.





23% did not feel comfortable discussing additional anemia management options for hospitalized patients with their providers.

On average, surveyed nurses expressed feeling only moderately confident in recognizing signs and symptoms of anemia in patients.



Comments revealed that anemia is typically addressed only when hemoglobin levels drop below 7 g/dL. Many respondents emphasized the need for additional education on anemia and its management.



## CONCLUSION


Nursing professionals demonstrate differing levels of confidence in recognizing the signs, symptoms, and management of anemia. This highlights the need for enhanced education across inpatient nursing divisions, particularly focusing on the relationship between hemoglobin levels and patient outcomes. In conclusion, advancing education and prioritizing anemia management within multidisciplinary healthcare teams are crucial for improving the quality of care for hospitalized patients.

## ACKNOWLEDGEMENTS

Thank you to the nursing staff of Mercy and Atrium Health for responding to this survey.

# What is anemia?

- Low hemoglobin, decreased oxygen delivery to tissues and organs
- Between 35-75% of patients admitted to the hospital develop anemia during their stay, and the prevalence is up to 100% in patients with ICU stays of >7 days. Of those who are anemic when discharged, about half are still anemic up to 12 months later<sup>1</sup>.



World Health Organization. Guidance on implementing patient blood management to improve global health status. Geneva: World Health Organization; 2024. Accessed December 26, 2025. <https://iris.who.int/>

# Blood Health...?



- Blood health is the optimal function of individual elements of blood and their associated interactions with all other organ systems.
- **Blood is an organ.**
- It is often treated or viewed as connective tissue, a commodity, a medicine, or a replacement fluid.
- Blood plays a pivotal role in overall human well-being.



Transfused patients may have **higher** hemoglobin but **worse** blood health.


World Health Organization. Guidance on implementing patient blood management to improve global health status. Geneva: World Health Organization; 2024. Accessed December 26, 2025. <https://iris/who.int/>

# Public Health & Blood Health Promotion



Ask yourself:  
does the current  
landscape of  
**effectively**  
promote blood  
health?

# The Impact of Poor Blood Health



- More than 3 billion individuals are affected by iron deficiency anemia, blood loss and coagulopathy<sup>2</sup>.
- This has profound macro-economic, public health and patient-level consequences<sup>2</sup>.
- Impaired blood health has a **disproportionate impact** on women's health, maternal health, and fetal, neonatal, and children's health<sup>2</sup>.
- Poor blood health during childhood and adolescence has many underrecognized consequences, and it exacerbates morbidities and comorbidities of older adults<sup>2</sup>.
- A transfusion is NOT a cure for anemia, and it does not improve overall blood health.**

# Anemia Should NOT be Normalized

- Anemia is common, but it is **NOT** benign.
  - Anemia is associated with **increased** morbidity, mortality, longer hospital stays, delayed healing, and higher healthcare costs.
- Anemia is a manifestation of an underlying disorder, **NOT** a diagnosis itself. Normalizing it risks missing treatable causes and perpetuating harm.

Even mild or asymptomatic anemia should be investigated and managed. Do not dismiss anemia as “normal.”

So... anemia and poor blood health are bad, but as an RN, what can I do about it?



# The Core Relationship



## Anemia Management

- Identify anemia and the type
  - Manage symptoms
  - Monitor hemoglobin response to treatment
  - Prepare and monitor transfusion when indicated

## Blood Health Promotion

- Prevent blood loss & iatrogenic anemia
- Support nutrition and hematopoiesis
- Reduce unnecessary transfusions
- Promote long-term self-management
- Support chronic disease control and equity


## Nursing Impact Zone

- Patient education (cause, treatment, prevention)
- Lab and blood conservation
  - Root-cause advocacy
- Transfusion stewardship and informed choice
- Monitoring response and preventing recurrence

Anemia management treats the problem; blood health promotion is about the overall well-being of an essential organ system.

**Nurses operate in the space where both happen at the same time.**


# The Nurse's Role Blood Health & Anemia Management



Early  
detection &  
assessment



Patient  
advocacy



Education



Collaboration

# The Nurse's Role in Blood Health Promotion

## INpatient Strategies

### Prevent Iatrogenic Anemia

- Use pediatric/low volume tubes when possible
- Bundle lab draws; avoid unnecessary daily/serial labs
- Closed-loop sampling devices: implement devices that return waste blood to the patient, especially for arterial lines

### Early Identification of Blood Disorders

- Monitor trends in labs rather than single values
- Assess for signs and symptoms of anemia, thrombocytopenia and coagulopathy
- Promptly escalate abnormalities to providers

### Transfusion Safety and Stewardship

- Ensure evidence-based transfusion thresholds are followed
- Perform accurate patient identification and blood component verification
- Education and auditing: regularly train staff and audit practices to reinforce blood conservation.

### Bleeding and Clot Prevention

- Assess anticoagulant use, bleeding risks, and fall risk
- Monitor surgical sites, drains, stool/urine for bleeding

### Nutrition Support

- Collaborate with dieticians to support iron, B12, folate intake
- Ensure patients with anemia receive appropriate supplements
- Collaborate with interdisciplinary team to optimize blood health through pharmacologic modalities when patients aren't eating well



# The Nurse's Role in Blood Health Promotion

## OUTpatient Strategies

### Screening and Early Detection

- Encourage routine CBCs for high-risk groups (older adults, pregnant patients, those with CKD, women with heavy menstrual bleeding)
- Screen for anemia symptoms and work with surgeons/OB-GYN to optimize patients prior to procedures (or delay elective procedures until hemoglobin has improved)

### Nutrition and Lifestyle Education

- Teach patients about iron-rich foods
- Encourage vitamin C with iron intake
- Educate on limiting substances that impair absorption (tea, calcium, PPIs)

### Medication and Supplement Education

- Teach correct iron administration
- Monitor for side effects (constipation, GI upset, or nonadherence)

### Chronic Disease Management

- Support patients with sickle cell disease, thalassemia, hemophilia, autoimmune disorders

### Public Health and Advocacy

- Educate patients on recognizing bleeding, potential blood clot formation, and symptoms of anemia and emphasize reporting it to providers
- Address health disparities affecting anemia



# Anemia Management & Education

## Help patients understand their anemia

Explain what anemia is and their specific type (iron deficiency, CKD-related, B12/folate deficiency).

Clarify symptoms patient should expect vs report urgently.

Reinforce that treatment targets the cause, not just the hemoglobin.

## Nutrition education

Identify iron-rich foods for patients.

Encourage vitamin C to improve absorption.

Review foods/meds that impair absorption.

Address cultural, financial, and access barriers.

Nurses translate **anemia management** into **patient action**.

How and when to take iron (oral vs IV).

## Medication and supplement teaching

Expected side effects and management strategies.

Importance of adherence!

*Education improves adherence, prevents recurrence, and reduces unnecessary transfusions.*

## Symptom monitoring

Teach patients to report worsening fatigue, dyspnea, dizziness, chest pain, palpitations, black tarry stools, hematuria, heavy menses.

## Promote long-term blood health


Prevent recurrence through ongoing nutrition, managing chronic conditions, avoiding unnecessary blood loss.

Encourage screening early and following up with routine appointments.

- **Collaboration is key.**
- Discuss preferences and wishes with patients.
  - Ensure that providers have sufficiently explained the risks, benefits, and alternatives to patients during the informed consent process for blood components.
- Work with providers and multidisciplinary team to explore non-transfusion treatment options (PO/IV Iron, B12, folate supplementation, erythropoiesis-stimulating agents).
- Participate in Patient Blood Management (PBM) Committees and initiatives to improve practice and outcomes.



# Big-Picture Difference



**Both are essential!**

# Practical Takeaways

*You make a difference!*

Do **NOT** normalize anemia:  
investigate and treat even mild cases.

Advocate for early detection and management: use evidence-based guidelines for anemia screening and treatment.

Minimize iatrogenic anemia: reduce unnecessary blood draws, use of blood-sparing techniques, and educate the team.

Empower patients: provide education, respect preferences, and ensure informed choice.

Engage in PBM: participate in committees, policy development, and continuous improvement.



Healthier patients!

# References

1. **World Health Organization.** *The urgent need to implement patient blood management: Policy brief.* Geneva: World Health Organization; 2021. Accessed December 26, 2025.  
<https://apps.who.int/iris/handle/10665/346655>
2. **World Health Organization.** *Guidance on implementing patient blood management to improve global health status.* Geneva: World Health Organization; 2024. Accessed December 26, 2025.  
<https://iris.who.int/>



**ADVOCATE**HEALTH

# Bloodless Medicine

**Bobbi Jo Tutterow, MSN, RN**  
**Wake Area**


# Jehovah's Witness (JW)

Jehovah's Witnesses believe that a human must not sustain his life with another creature's blood, and they recognize no distinction "*between taking blood into the mouth and taking it into the blood vessels.*" It is their deep-seated religious conviction that Jehovah will turn his back on anyone who receives blood transfusions.

"Only flesh with its life, its blood, *you must not eat.*" Genesis 9:4

*"Just be firmly resolved not to eat the blood, because the blood is the life, and you must not eat the life."* Deuteronomy 12:23

# Unacceptable vs. Individual Decision



**Clotting factors** = proteins in the blood to control clotting (factors I, VIII, XIII)

**Blood fractions** = proteins found in the blood plasma (anti-venoms; immune globulin)

**Albumin** = protein found in the plasma, produced in the liver

# Healthcare Team Response

- Be prepared for the challenges of treating no blood patients
- Be aware of blood alternatives
- **Have respect for the patient's autonomy and human rights even if this amounts to death for lack of blood transfusion**



# Position on Medical Treatment

- They are cooperative with medical professionals
- It is not their intent to exercise the right to die
- All forms of medical treatment are acceptable with the exception of blood transfusions



# Common Theme for JW Patients

- Loss of confidence in the medical system
- Feelings of mistrust between the patient and the healthcare team
- Fear and anxiety
- Discord between patient and the healthcare team

# Healthcare Team Response

“It may be tempting to engage a patient refusing blood in debate. However, this casts the clinician into an adversarial role ... An alternate approach involves serving as the patient's advocate, with the focus on *finding the best possible therapy* within the boundaries of the patient's religious beliefs and comfort zone (i.e., values and preferences).”

(Crookston, 2013)

## Documenting Patient's Wishes Regarding Blood Products

**NOTE:** This is not the patient's consent for blood. This is intended to be documented/reviewed every visit and allows for the healthcare team to be aware of the patient's wishes across encounters.

**Blood Admin**

**Blood Product Refusal**

Does the patient have a religious or personal belief that prevents them from receiving medically indicated blood transfusions?  No  Yes

A blood product refusal Patient FYI flag will be added to the patient's record. To remove the flag, update the answer above to "No".

Reprint the patient's armband to add/remove "NO BLOOD" text.

Update patient's religion (if needed):  Jehovah's Witness  No Blood Products

Unable to discuss blood product consent

Last reviewed by [redacted] on 1/10/2024 at 12:44 PM


## Alerts When Blood Product Refusal Present



**TS**  
Testtwo Surgical  
Female, 52 y.o., 12/7/1971  
MRN: 300108512  
CSN: 6920132082  
Bed: WFM11AWL-11AWL-00  
Cur Location: WFM11AWL-00

**Patient FYIs**  
Blood Products Refusal  
Added automatically based on the patient's answer of "Yes" to question: Does the patient have a religious or personal belief that prevents them from receiving medically indicated blood transfusions?  
AYR Appropriate WITH Assistance

## FYI Flag “Blood Products Refusal”



**BestPractice Advisory - Surgical, Testtwo**

**The patient has refused blood products.**

Please discuss this with the patient and take one of the following actions:

1. **Accept** to remove all orders from the orderset
2. **Override once** to proceed with the orders without changing the patient's preference (patient will refuse future blood products)
3. **Always allow** to proceed with the orders and remove the blood product refusal FYI flag. (patient will accept future blood products)

**Remove the following orders?**

Remove	Keep
Remove	Keep
Remove	Keep
Remove	Keep

**Verify informed consent**  
Routine, Once, today at 1255, For 1 occurrence


**Transfuse Red Blood Cells , 1 Units**  
Routine, Transfuse 1 Units Use blood warmer? No Initial rate instructions: Begin at slow rate of ...

**Prepare Red Blood Cells : 1 Units**  
Prepare 1 Units Does this patient have Sickle Cell Disease? No Donor source: Allogeneic

**sodium chloride 0.9 % infusion**  
30 mL/hr, intravenous, Continuous PRN, For use with blood product infusion to flush line at rate...

**Acknowledge Reason**  
Override once - Patient will accept blo... Always allow - Patient will accept blood...


**Accept**



**Summary**   **Chart Review**   **MAR**   **Flowsheets**   **Notes**   **Education**   **Care Plan**   **Orders**   **Charge Capture**   **Surgical**   **Navigators**   **Pre-op**

**BLOOD PRODUCTS REFUSAL** Click HERE to review or update

## Banner near top of Patient Summary “Overview”



**Red Blood Cells (# Units)**

**BLOOD PRODUCTS REFUSAL** Click HERE to review or update

**Consents**  
No documents found

**Type and Screen**

**Latest Orders**

Type and screen	Ordered On	Latest Result	Ordered By
Type and screen	01/10/24 0936	-	Joshua Eichenberger, MD

**Last Resulted Components**  
No lab results found.

**Blood Type**  
No blood type on file.

**Blood Transfusion Orders**  
(From admission, onward)

**Transfusions already released**

Ordered	Start
01/10/24 0936 > Transfuse Red Blood Cells Transfusion (1 of 1 released) Reprint	01/10/24 0935

**Transfusion History**  
(Past 4 Days)

PRBC	Not Started	Start	End
Not Started (1 unit)			

**Transfusion indication**

- Active bleeding independent of hemoglobin
- Hgb LESS THAN 7 g/dL (Hct LESS THAN 21%)
- Hgb LESS THAN 7.5 g/dL (Hct LESS THAN 22%)
- Hgb LESS THAN 8 g/dL (Hct LESS THAN 24%)
- Transfusion in Sickle Cell Disease Other

**Has consent been obtained?**

**Special requirements**

**Does this patient have Sickle Cell Disease?**

**Prepare for**

**Donor source**

**Additional Info** (will appear in order display name)

**Comments**

**Transfuse Red Blood Cells , 1 Units**  
Routine, Transfuse 1 Units Use blood warmer? No

BPA when attempted to order blood product(s)

# “No Blood” Card



“I direct that no blood transfusions (whole blood, red cells, white cells, platelets or plasma) be given to me under any circumstance, ***even if deemed necessary to preserve my life or health...***”

- **Paragraph 6:** Clearly print or type any further directions regarding fractions, procedures, current medications, allergies, and medical problems.
- **Paragraph 7:** The *Advance Medical Directive* should be signed in front of two witnesses, both of whom must be present when you sign the document. Persons related to you by blood, marriage, or adoption, and persons under age 18 (19 in British Columbia) should not sign as witnesses.
- **Emergency Contacts:** The *Advance Medical Directive* does not authorize persons named as your emergency contacts to make health care decisions for you. The purpose of this section is to provide your doctor with the name and telephone number, including area code, of persons you would like contacted if you are unconscious or incapable.
- **Power of Attorney for Personal Care:** If you have a power of attorney for personal care (also called a "living will") authorizing one or more persons to make health care decisions for you, then you may wish to name as the emergency contacts on your *Advance Medical Directive* the same persons appointed in your power of attorney for personal care.
- **Edits or Alterations:** Edits or alterations to the *Advance Medical Directive* should not be made after the document has been signed, dated, and witnessed. Otherwise, the document might be considered legally invalid. Edits or alterations to the information in your *Advance Medical Directive* should be made on a replacement card that is subsequently signed, dated, and witnessed.

<p><b>ADVANCE MEDICAL DIRECTIVE</b></p> <p>1. I, _____, make this advance directive as a formal statement of my wishes. These instructions reflect my resolve and informed decision.</p> <p>2. I direct that <u>no blood transfusions</u> (whole blood, red cells, white cells, platelets, or blood plasma) be given to me under any circumstances, even if deemed necessary to preserve my life or health. I accept no alternative treatments that would result in the same effect as the avoidance of production of blood cells, and other bloodless management.</p> <p>3. This directive is an exercise of my right to decide medical treatment in accord with my deeply held values and convictions. I am one of Jehovah's Witnesses, and I make this directive out of obedience to commands in the Bible, such as: "Keep abstaining . . . from blood."—Acts 15:28, 29.</p> <p>4. Regarding minor fractions of blood, my instructions are: [initial those that apply]</p> <p>(a) <input type="checkbox"/> I REFUSE ALL. (b) <input type="checkbox"/> I REFUSE ALL EXCEPT: _____</p> <p>(c) <input type="checkbox"/> I may be willing to accept some minor blood fractions. But the details will have to be discussed with me if I am conscious.</p> <p>5. Regarding medical procedures involving the use of my blood, I direct that pre-donate and store my blood for later transfusion. I accept no other procedures such as blood testing.</p> <p>My other instructions regarding use of my blood are: [initial those that apply]</p> <p>(a) <input type="checkbox"/> I REFUSE ALL. (b) <input type="checkbox"/> I REFUSE ALL EXCEPT: _____</p> <p>(c) <input type="checkbox"/> I may be willing to accept certain medical procedures involving my blood, but the details will have to be discussed with me if I am conscious.</p> <p>6. Additional Instructions [this may be left blank]</p> <p>_____</p> <p>_____</p> <p style="text-align: right;">Printed in Canada</p>		<p><b>Open to Advance Medical Directive •</b></p> <p><b>7. Signature and Witnesses:</b> The maker of this document signed in both our presence. We are not related to the maker by blood, marriage, or adoption.</p> <p>Signature of maker _____ Date _____</p> <p>Address _____ Province _____ Postal Code _____</p> <p>Signature of witness No. 1 _____ Print name _____ Telephone _____ Address _____</p> <p>Signature of witness No. 2 _____ Print name _____ Telephone _____ Address _____</p> <p><b>NO BLOOD</b></p> <p><b>MEDICAL DIRECTIVE</b></p> <p>In case of emergency, please contact:</p> <p>Name _____ Telephone No. 1 _____ Signature No. 1 _____ Name _____ Telephone No. 2 _____ Signature No. 2 _____ Name _____ Telephone No. 3 _____ Signature No. 3 _____</p> <p style="text-align: center;">(Signed document inside)</p>
---	--	---

Major Components			<p><b>Red Blood Cells</b>            Cells that transport oxygen from the lungs to the body cells            *Must complete Blood Transfusion Consent form if patient accepts RBC.</p>
			<p><b>Fresh Plasma</b>            Liquid part of blood made of water, ions, sugar, hormones and protein            *Must complete Blood Transfusion Consent form if patient accepts fresh plasma.</p>
			<p><b>Platelets</b>            Cells that prevent blood loss by stopping the bleeding at the site of injury            *Must complete Blood Transfusion Consent form if patient accepts platelets</p>
Plasma Derived Proteins	Accept	Refuse	
			<p><b>Albumin</b>            Protein extracted from plasma. Used as a blood volume expander. Also used in medications such as erythropoietin and neupogen. <i>Examples: 5% and 25% Albumin</i></p> <p><b>Clotting Factors</b>            Various proteins extracted from plasma used to stop active bleeding. <i>Examples: prothrombin complex concentrate (FEIBA), prothrombin complex concentrate (Kcentra), Recombinant fibrinogen (Ristap), factor VIIa (Novoseven), cryoprecipitate</i></p> <p><b>Immunoglobulins</b>            Proteins extracted from plasma used to provide immunity, improve immune response to infections and Rh incompatibility (RhoGam). <i>Examples: Rh Immunglobulin</i></p>
White Blood Cell Derived Proteins			<p><b>Platelet Gel Autologous</b>            Platelet rich plasma, centrifuged from the patient's blood and applied to surgical sites to reduce bleeding and enhance healing.</p> <p><b>Sealants</b>            Proteins from plasma. Used to stop bleeding. <i>Examples: pharmacy carries topical recombinant thrombin (Recothrom), WF stock Tisseel, Gel foam, BioGlue, Fibrin Glue, and Autologous Platelet Gel.</i></p>
	Accept	Refuse	
Equipment and Procedures	Accept	Refuse	<p><b>Interferon</b>            Protein extracted from white blood cells. Used for cancer treatments and viral infections. <i>Examples: Interferon alfa-2b (Intron A)</i></p> <p><b>Cell Salvage (saver)</b>            Patient's shed blood is retrieved, filtered and returned in a closed loop process generally during a surgical procedure.</p>

Equipment and  
Procedures

**Epidural Blood Patch**

Patient's blood is removed from the vein and injected into spinal membrane to seal a spinal leak.

**Heart-Lung Machine**

Patient's blood is directed to a cardiopulmonary bypass pump that oxygenates and returns the blood during cardiovascular surgery.

**Hemodilution (ANH)**

Specific amounts of patient's blood is removed at initiation of surgery and replaced with intravenous fluids. Blood is then returned in a closed loop process at the end of the procedure.

Patient or Legal Representative Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_ am pm

Witness Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_ am pm

(\*Witness only needed if patient unable to sign)

I have personally explained the above information to the patient or the patient's legal representative:

Reviewer Signature: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_ am pm

Interpreter Signature / ID #: \_\_\_\_\_ Date: \_\_\_\_\_ Time: \_\_\_\_\_ am pm



**ADVOCATE**HEALTH

# **Nursing's Role in Safe Transfusion Practice**

**Beth Halperin, BSN, RN**  
**Illinois and Wisconsin Division**

# From ‘Notes on Nursing’

“Let whoever is in charge keep this simple question in her head:


Not, how can I always do this right thing myself, but how can I provide for this right thing to be always done?”

*Florence Nightingale, 1859*




ADVOCATE HEALTH

# High Reliability Organizations




# HRO's Create Safety

- These organizations perform risky, dangerous, complex tasks every day in difficult, unforgiving environments
- Manage to do so safely – almost all the time – without hurting anyone, or failing operationally
- Share five characteristics or organizational values
  - Sensitivity to operations
  - Reluctance to simplify
  - Preoccupation with failure
  - Deference to expertise
  - Resilience



Both Nursing Leaders and Direct Care Nurses Create Safety

# Last Chance to Prevent Error



- The players: Lab, Physician, Transfusion Service, Nursing
- **The Nurse at the bedside is the last link in the Transfusion Process**
  - The last chance to create safety:
    - Catch errors / wrong transfusions
    - Detect Transfusion Reactions

# The Leadership Cascade: Creating Clarity about the Mission

# Nursing Leadership's Role

What HRO Leaders Think	What You See and Hear
Challenge the status quo	"We can do better – act on knowledge
Inspire a shared vision; communicate it	"It's not just a transfusion...it's a transplant" "Seven is the new ten, one is the new two"
Build teams; enable others to act	"We are in this together" "How do we get the message across in this unit?"
Model the way, walk the talk	"Transfusion safety is job one and I expect us to act that way"
Encourage their people with visible signs of support; advocate for their teams	If challenged: "My teams put transfusion safety first" Remove obstacles; challenge others to join in the 'we can do better' movement



**The Leadership Jigsaw**

# Direct Care Nurses

- Nurses must receive the same educational message physicians receive
- Nursing must support and participate in the development of Patient Blood Management Committees
- Provide input on policies and procedures that address blood product transfusions administration and signs and symptoms of transfusion reaction.
- Build accountability by audits of nursing transfusion practice



# Acting on Knowledge

- A nurse working on a medical surgical unit was caring for a 50 year old man who had been admitted for a suspected pneumonia
- The physician wrote an order for 2 units of packed red cells
- *“He doesn’t look like a 7 to me”*
- Checked the labs – Hgb was 11 grams
- Called the physician to check the order
- Physician agreed – ‘cancel the transfusion’



# Final thoughts...

- Start with ‘why’: Communicate the link between blood product use and Patient Safety
- Nurses should receive the same educational message as physicians
- Communicate the message everywhere – make the message easy to remember
- Nursing leadership should support the direct care nurse’s role in safe transfusion practice

# References

Managing the Unexpected: Sustained Performance in a Complex World, Third Edition. Weick KE, Sutcliffe KM. San Francisco, CA: Jossey-Bass; 2015. ISBN-13: 9781118862414.

Becoming a High Reliability Organization: Operational Advice for Hospital Leaders. Hines S, Luna K, Lofthus J, et al. Rockville, MD: Agency for Healthcare Research and Quality; February 2008. AHRQ Publication No. 08-0022. [\[Free full text\]](#)

Chassin MR, Loeb JM. High-reliability health care: getting there from here. *Milbank Q.* 2013;91:459-490. [\[Free full text\]](#)

Rochlin GI. Safe operation as a social construct. *Ergonomics*. 1999;42(11):1549-1560. [\[Available at\]](#)

Wears RL, Roberts KH, eds. Special issue, Safety Science, High reliability organizations and resilience engineering. *Saf Sci*. 2019;117:458-459. [\[Available at\]](#)

# Q&A

## My Account



My Account



My Pending Activities



My Transcript



Edit My Profile



Add/Edit Mobile Number

## Claiming Credit

1. Text code **GULNUY** to (414) 219-1219
2. You will also receive a reminder email within 24 hours with instructions on how to claim your credit
3. To fully claim credit, go to "MY ACTIVITIES/Pending Activities" tab to complete evaluation and/or assessment

**Texting the code alone will not give your credit. You will need to go online.**

Please direct any related IPCE questions to [cme@aah.org](mailto:cme@aah.org)

# Nursing Grand Rounds

Sponsored by Enterprise NGR Committee & System Nursing Research

February 19<sup>th</sup> 2026

3-4 pm Central

4-5 pm Eastern

## *Elevating CPR Mastery Using RQI Approach*

### **Presenters:**

**Julia Reynolds, MSN, RN, NE-BC**

Advocate Center for Life Support Education

**Kelley Sava, MS, APN, CPNP-PC**

Advocate Simulation Program

**Steven Cuzmenco, MSN, RN, NPD-BC, CCRN-CMC, CV-BC**

Advocate Center for Life Support Education

### **Overview:**

In the United States, only 25% of patients survive an in-hospital cardiac arrest. High-quality CPR is the single highest determinant of survival from cardiac arrest. Resuscitation Quality Improvement (RQI) methodology offers a new standard of care that shifts resuscitation practice from course completion to everyday competence. This program will feature experts who will share details about how they are improving care and outcomes across the enterprise.

Scan here to register and receive an email with calendar invite **or** join day of

Registration on the CE Learning Platform: [\*\*Click here to Register\*\*](#)



 **ADVOCATE** HEALTH